John R. Lukens

The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis

Innate immune signaling through inflammasome activation has been implicated in the pathogenesis of multiple sclerosis (MS). We previously demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs), drugs approved to treat HIV and hepatitis B virus infections, and kamuv...